Burn, Edward http://orcid.org/0000-0002-9286-1128
Roel, Elena http://orcid.org/0000-0002-1964-3546
Pistillo, Andrea http://orcid.org/0000-0002-4467-0220
Fernández-Bertolín, Sergio
Aragón, Maria http://orcid.org/0000-0002-5990-6953
Raventós, Berta
Reyes, Carlen
Verhamme, Katia
Rijnbeek, Peter http://orcid.org/0000-0003-0621-1979
Li, Xintong http://orcid.org/0000-0002-6872-5804
Strauss, Victoria Y.
Prieto-Alhambra, Daniel http://orcid.org/0000-0002-3950-6346
Duarte-Salles, Talita http://orcid.org/0000-0002-8274-0357
Funding for this research was provided by:
DH | National Institute for Health Research (SRF-2018-11-ST2-004)
Article History
Received: 20 August 2021
Accepted: 1 November 2022
First Online: 23 November 2022
Competing interests
: D.P.A.’s research group has received research grants from the European Medicines Agency, from the Innovative Medicines Initiative, from Amgen, Chiesi, and from UCB Biopharma; and consultancy or speaker fees from Astellas, Amgen and UCB Biopharma. The remaining authors declare no competing interests’